Synchronous global assessment of gene and protein expression in colorectal cancer progression

被引:50
作者
Kwong, KY
Bloom, GC
Yang, I
Boulware, D
Coppola, D
Haseman, J
Chen, E
McGrath, A
Makusky, AJ
Taylor, J
Steiner, S
Zhou, J
Yeatman, TJ
Quackenbush, J
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Surg & Interdisciplinary Onocl, Tampa, FL 33612 USA
[2] Inst Genom Res, Rockville, MD 20850 USA
[3] Large Scale Biol Corp, Germantown, MD USA
[4] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
D O I
10.1016/j.ygeno.2005.03.012
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Well-established models of colorectal cancer progression are based on the idea that the disease evolves through a multistep process involving sequential genetic mutations, suggesting that progression through clinically defined stages should correlate with well-defined patterns of gene expression. The majority of studies to date, however, have assessed these processes one gene and one protein at a time. We report the first comprehensive assessment of both gene and protein expression performed in parallel across progressive stages of human colorectal neoplasia. Remarkably, despite the global nature of the gene expression assessment, very few genes could be linked with certainty to specific proteins through currently available annotations. Furthermore, the correlation of expression between identified genes and proteins was poor. Nevertheless, both produced expression signatures that differentiated normal mucosa and nonmalignant adenomas from each other and from the malignant carcinomas and both produced fairly consistent subclasses of the malignancies, suggesting that a molecular staging might be more appropriate provided that these profiles can be tied to clinical outcome. This is potentially important as clinical staging is widely used as a prognostic indicator and used in the decision to pursue adjuvant therapies. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:142 / 158
页数:17
相关论文
共 45 条
[11]  
Chen TA, 2003, CANCER RES, V63, P4368
[12]   Cycling to cancer with cyclin D1 [J].
Diehl, JA .
CANCER BIOLOGY & THERAPY, 2002, 1 (03) :226-231
[13]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[14]   Tumor induction of VEGF promoter activity in stromal cells [J].
Fukumura, D ;
Xavier, R ;
Sugiura, T ;
Chen, Y ;
Park, EC ;
Lu, NF ;
Selig, M ;
Nielsen, G ;
Taksir, T ;
Jain, RK ;
Seed, B .
CELL, 1998, 94 (06) :715-725
[15]  
GIOMETTI CS, 1980, CLIN CHEM, V26, P1152
[16]  
GIOMETTI CS, 1979, CLIN CHEM, V25, P1877
[17]  
GIOMETTI CS, 1981, CLIN CHEM, V27, P1918
[18]   The Hsp90 chaperone complex as a novel target for cancer therapy [J].
Goetz, MP ;
Toft, DO ;
Ames, MM ;
Erlichman, C .
ANNALS OF ONCOLOGY, 2003, 14 (08) :1169-1176
[19]  
Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO
[20]  
2-4